Nature Reviews Drug Discovery contents April 2016 Volume 15 Number 4 pp 217-292

If you are unable to see the message below, click here to view.

Advertisement
DOWNLOAD THE PROTEIN BIOMARKER DISCOVERY IN CANCER RESEARCH BUNDLE  For decades, cancer research advanced due to genomics. The study of proteins in human cells brought many new opportunities for more advancement, and also many challenges. We have put together a bundle that describes these challenges and an introduction to a technology that can help you overcome them.
TABLE OF CONTENTS
April 2016 Volume 15 Number 4		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Development of immuno–oncology drugs — from CTLA4 to PD1 to the next generations Axel Hoos	Want to speed up your antibody drug screening? Attend this complimentary webinar to learn how our new recombinant antibody platform can help Register Now
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
This animation explores progress in the development of oral anticoagulants that target components of the blood coagulation cascade to inhibit blood clotting in high-risk patients, as well as recent advances with antidotes to reverse the effects of oral anticoagulants when necessary. Watch now and download a poster on Anticoagulant drugs. Produced with support from: Boehringer Ingelheim
Advertisement
ESO, CNIO and NRCO Conference on FAMILIAL CANCER Presented by: European School of Oncology | Centro Nacional de Investigaciones Oncológicas | Nature Reviews Clinical Oncology May 19-20, 2016 | Madrid, Spain REGISTER NOW!
Comment: Putting translational science on to a global stage C. Taylor Gilliland, Dorit Zuk, Petr Kocis, Mike Johnson, Stewart Hay, Marian Hajduch, Florence Bietrix, Gregorio Aversa, Christopher P. Austin & Anton E. Ussi p217 | doi:10.1038/nrd.2016.33 Global collaboration in translational science promises to accelerate the discovery, development and dissemination of new medical interventions. Here, we introduce a new international collaboration of translational science organizations and highlight our initial strategy to reduce or remove bottlenecks in translation. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Deuterated drugs draw heavier backing Asher Mullard p219 | doi:10.1038/nrd.2016.63 The FDA is considering a first approval of a deuterated drug, and large pharmaceutical companies have started to incorporate 'heavy hydrogen' into novel candidates. PDF
European Lead Factory hits its stride Katie Kingwell p221 | doi:10.1038/nrd.2016.64 A large European drug discovery consortium is making inroads into novel chemical and biological space. PDF
NEWS IN BRIEF European regulators launch 'breakthrough' equivalent programme Asher Mullard p223 | doi:10.1038/nrd.2016.65 PDF
NEWS IN BRIEF Amarin agreement opens off-label promotion door Asher Mullard p223 | doi:10.1038/nrd.2016.66 PDF
BIOBUSINESS BRIEFS Patent watch: Modulating the human microbiome with live biotherapeutic products: intellectual property landscape Xiaowei Sun, Jeannette L. A. Fiala & Drew Lowery p224 | doi:10.1038/nrd.2016.48 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q2 2016 Jeffrey Stevens p225 | doi:10.1038/nrd.2016.49 PDF
AN AUDIENCE WITH Arthur Caplan p226 | doi:10.1038/nrd.2016.61 Arthur Caplan, a medical ethicist at the New York University School of Medicine, discusses how to fairly distribute experimental drugs outside of clinical trials. PDF
FROM THE ANALYST'S COUCH The non-small-cell lung cancer drug market Khurram Nawaz & Rachel M. Webster p229 | doi:10.1038/nrd.2016.42 The year 2015 saw the approval of six new targeted therapies for the treatment of non-small-cell lung cancer (NSCLC). This analysis discusses recently approved as well as late-stage compounds and examines how different drug classes will affect the NSCLC market. PDF
RESEARCH HIGHLIGHTS Top Drug delivery: Nanoparticles improve profile of molecularly targeted cancer drug p231 | doi:10.1038/nrd.2016.60 PDF Antifungals: Protein-protein interaction inhibitor tackles drug resistance p232 | doi:10.1038/nrd.2016.50 PDF Antimalarials: Novel proteasome inhibitor combats malaria p232 | doi:10.1038/nrd.2016.58 PDF Autoimmunity: Nanoparticles engineered for antigen-specific immunotherapy p233 | doi:10.1038/nrd.2016.62 PDF Infectious diseases: Cattle engineered to produce human antibodies against coronavirus p234 | doi:10.1038/nrd.2016.59 PDF IN BRIEF Drug screening: Inhibiting protein-protein interactions | Pain: FKBP51 inhibition reduces chronic pain | Cardiomyopathy: Inhibiting sarcomere contraction | Infectious disease: TLR7 activation fights resistance PDF Drug Discovery JOBS of the week Postdoctoral Research Fellow in Medicinal Chemistry for Cancer Drug Discovery University of Michigan Professor and Chair of Department of Immunotherapeutics & Biotechnology Texas Tech University Health Sciences Center Institute Research Scientist Target Biology The University of Texas MD Anderson Cancer Center Research Scientist I, Calcium Biology Broad Institute Two associate senior lecturers in peptide pharmaceuticals Uppsala University More Science jobs from Drug Discovery EVENT 5th Antiviral Drugs Research & Development Conference 01.06.16 San Diego, USA More science events from
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way  From tracking cancer biomarkers to quantifying rare mutations, gene editing events, and miniscule viral loads, Droplet Digital PCR has led to more discoveries than any other digital PCR platform. Visit our ddPCR page for application guides, publication lists, and webinars that explore the world of Droplet Digital PCR. Learn more
PERSPECTIVES		Top
OUTLOOK Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations Axel Hoos p235 | doi:10.1038/nrd.2015.35 Immuno-oncology has become the fastest-growing area in the pharmaceutical industry. In this Perspective, Hoos provides an overview of the history of immuno-oncology and investigates the factors that have led to its success. Moreover, he discusses the three generations of immunotherapies that have been developed since 2011 and provides an outlook to the future directions of drug discovery and development in immuno-oncology. Abstract | Full Text | PDF
REVIEWS		Top
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies Giovanni Musso, Maurizio Cassader & Roberto Gambino p249 | doi:10.1038/nrd.2015.3 Non-alcoholic steatohepatitis (NASH) is increasing in prevalence, partially because of the pervasiveness of obesity. In this Review, Musso and colleagues discuss potential future approaches to treat this disease, including those that target causes, such as inflammation and aberrant metabolism, as well as those that target fibrosis, one of the key features of patients with NASH. Abstract | Full Text | PDF | Supplementary information
From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery William A. Banks p275 | doi:10.1038/nrd.2015.21 Research on the blood-brain barrier (BBB) has led to the concept of a complex, dynamic interface between the central nervous system (CNS) and periphery. Banks considers how this new understanding can combine with classical concepts to inform CNS drug delivery strategies and promote BBB integrity in various diseases. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases Lluís Ballell, Mike Strange, Nicholas Cammack, Alan H. Fairlamb & Leszek Borysiewicz p292 | doi:10.1038/nrd.2016.51 Full Text | PDF | Supplementary information
Corrigendum: Biopharma deal-making in 2015: changing the pharma landscape Amanda Micklus & Steven Muntner p292 | doi:10.1038/nrd.2016.52 Full Text | PDF
Erratum: Pioneering apoptosis-targeted cancer drug poised for FDA approval Asher Mullard p292 | doi:10.1038/nrd.2016.53 Full Text | PDF
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions – explore the benefits of submitting your next manuscript to the journal.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.